AHAnette Henriksen

Anette Henriksen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anette Henriksen has a total of 163 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prediction of antibody non-specificity using protein language models and biophysical parameters

    by Laila I. Sakhnini, Ludovica Beltrame, Simone Fulle, Pietro Sormanni, Anette Henriksen, Nikolai Lorenzen, Michele Vendruscolo, Daniele Granata

    The development of therapeutic antibodies requires optimizing target binding affinity and pharmacodynamics, while ensuring high developability potential, including minimizing non-specific binding. In this study, we address this problem by predicting antibody non-specificity by two complementary approaches: (1) antibody sequence embeddings by protein language models (PLMs) and (2) a comprehensive set of sequence-based biophysical descriptors. We benchmark the PLM embeddings against interpretable, sequence-derived biophysical descriptors and use fragment-specific models (variable heavy (VH) and variable light (VL) chains, concatenated regions, and individual complementary-determining regions (CDRs) to identify region-level determinants of non-specificity in functional antibodies that bind defined targets. These models were trained on previously published human and mouse antibody data and tested on three public datasets. We show that non-specificity is best predicted from the VH domain and heavy-chain CDRs. These region-level analyses show that heavy-chain features, especially H-CDR3, dominate the predictive signal. The top performing PLM, a VH domain-based Evolutionary Scale Modeling 1 v LogisticReg model, resulted in 10-fold cross-validation accuracy of up to 71%. While predictive accuracy is comparable to classical machine-learning baselines, PLM-based embeddings provide sequence-context representations that yield consistent region-level attribution and provide complementarity to the classical models by enhancing the reliability of predicted non‑specificity scores when used in combination. Our biophysical descriptor-based analysis identified the isoelectric point as a key driver of non-specificity, consistent with previous reports. Our findings highlight the importance of biophysical properties in predicting antibody non-specificity and highlight the potential of PLMs for the development of antibody-based therapeutics. These conclusions are robust to alternative class definitions and are not driven by VH-VL mutational bias. We illustrate the generalizability and practical use of the PLM approach by extending it to therapeutic antibodies and nanobodies, providing a tool for early-stage developability assessment, and we make the models publicly available.


  • Open Access

    Prediction of Antibody Non-Specificity using Protein Language Models and Biophysical Parameters

    by Laila I. Sakhnini, Ludovica Beltrame, Simone Fulle, Pietro Sormanni, Anette Henriksen, Nikolai Lorenzen, Michele Vendruscolo, Daniele Granata

    The development of therapeutic antibodies requires optimizing target binding affinity and pharmacodynamics, while ensuring high developability potential, including minimizing non-specific binding. In this study, we address this problem by predicting antibody non-specificity by two complementary approaches: (i) antibody sequence embeddings by protein language models (PLMs), and (ii) a comprehensive set of sequence-based biophysical descriptors. These models were trained on human and mouse antibody data from Boughter et al . (2020) and tested on three public datasets: Jain et al . (2017), Shehata et al . (2019) and Harvey et al . (2022). We show that non-specificity is best predicted from the heavy variable domain and heavy-chain complementary variable regions (CDRs). The top performing PLM, a heavy variable domain-based ESM 1v LogisticReg model, resulted in 10-fold cross-validation accuracy of up to 71%. Our biophysical descriptor-based analysis identified the isoelectric point as a key driver of non-specificity. Our findings underscore the importance of biophysical properties in predicting antibody non-specificity and highlight the potential of protein language models for the development of antibody-based therapeutics. To illustrate the use of our approach in the development of lead candidates with high developability potential, we show that it can be extended to therapeutic antibodies and nanobodies.

  • Open Access

    A comparative analysis of heterogeneity in commercially available recombinant factor VIII products

    by D. Baunsgaard, A. D. Nielsen, P. F. Nielsen, A. Henriksen, A. K. Kristensen, H. W. Bagger, M. Ezban

    Introduction: Advances in analytical technologies enable investigation of possible correlations between molecular structure, aggregation and subvisible particle content. Regulatory agencies place increasing attention on potential risks associated with protein aggregates in the micron range in biological therapeutics.Aim: Assess the heterogeneity, high‐molecular‐weight protein (HMWP) species, subvisible particle content and posttranslational modifications in six commercially available recombinant FVIII (rFVIII) products.Methods: Three B‐domain‐deleted (BDD) or B‐domain truncated rFVIII products (turoctocog alfa, simoctocog alfa and moroctocog alfa) and three full‐length rFVIII products (octocog alfa FS and two octocog alfa) were analysed. HMWP content, amount of micron range subvisible particles, tyrosine‐1680 sulphation and N‐glycan analysis were investigated.Results: The B‐domain‐modified products had more protein size homogeneity vs the full‐length products. Size exclusion‐high‐performance liquid chromatography data indicated no association between B‐domain structure and aggregate content or size of the products tested. The rFVIII products showed large variation in subvisible particle concentration, with turoctocog alfa and simoctocog alfa having the lowest numbers (1000‐1600 and 1800‐2400 particles/100 IU, respectively). Turoctocog alfa and simoctocog alfa displayed the most complete tyrosine sulphation (>99.5%).Conclusion: Overall, there was no association between molecular structure (full‐length B‐domain, BDD or truncated) and subvisible particle or HMWP content. Dissimilarities may be related to production and product handling differences. In this study, turoctocog alfa, such as simoctocog alfa, had one of the lowest levels of subvisible particles and HMWP content, and high protein size homogeneity.


  • A Comprehensive Evaluation of Nanoparticle Tracking Analysis (NanoSight) for Characterization of Proteinaceous Submicron Particles

    by Xinsheng Tian, M. Reza Nejadnik, Dorrit Baunsgaard, Anette Henriksen, Christian Rischel, Wim Jiskoot


  • Seed thioredoxin h

    by Per Hägglund, Christine Finnie, Hiroyuki Yano, Azar Shahpiri, Bob B. Buchanan, Anette Henriksen, Birte Svensson


  • Structure and function of α-glucan debranching enzymes

    by Marie Sofie Møller, Anette Henriksen, Birte Svensson

    α-Glucan debranching enzymes hydrolyse α-1,6-linkages in starch/glycogen, thereby, playing a central role in energy metabolism in all living organisms. They belong to glycoside hydrolase families GH13 and GH57 and several of these enzymes are industrially important. Nine GH13 subfamilies include α-glucan debranching enzymes; isoamylase and glycogen debranching enzymes (GH13_11); pullulanase type I/limit dextrinase (GH13_12–14); pullulan hydrolase (GH13_20); bifunctional glycogen debranching enzyme (GH13_25); oligo-1 and glucan-1,6-α-glucosidases (GH13_31); pullulanase type II (GH13_39); and α-amylase domains (GH13_41) in two-domain amylase–pullulanases. GH57 harbours type II pullulanases. Specificity differences, domain organisation, carbohydrate binding modules, sequence motifs, three-dimensional structures and specificity determinants are discussed. The phylogenetic analysis indicated that GH13_39 enzymes could represent a “missing link” between the strictly α-1,6-specific debranching enzymes and the enzymes with dual specificity and α-1,4-linkage preference.


  • Open Access

    Crystal Structure of Barley Limit Dextrinase-Limit Dextrinase Inhibitor (LD-LDI) Complex Reveals Insights into Mechanism and Diversity of Cereal Type Inhibitors

    by Marie Sofie Møller, Malene Bech Vester-Christensen, Johanne M. Jensen, Maher Abou Hachem, Anette Henriksen, Birte Svensson


  • Oligosaccharide and Substrate Binding in the Starch Debranching Enzyme Barley Limit Dextrinase

    by Marie S. Møller, Michael S. Windahl, Lyann Sim, Marie Bøjstrup, Maher Abou Hachem, Ole Hindsgaul, Monica Palcic, Birte Svensson, Anette Henriksen


  • Open Access

    Crystal Structure of the Chlamydomonas Starch Debranching Enzyme Isoamylase ISA1 Reveals Insights into the Mechanism of Branch Trimming and Complex Assembly

    by Lyann Sim, Sophie R. Beeren, Justin Findinier, David Dauvillée, Steven G. Ball, Anette Henriksen, Monica M. Palcic


  • A chromogenic assay for limit dextrinase and pullulanase activity

    by Marie Bøjstrup, Caspar Elo Christensen, Michael Skovbo Windahl, Anette Henriksen, Ole Hindsgaul